NEW YORK (GenomeWeb News) – Gene editing firm Editas Medicine today announced it has secured $43 million in Series A financing.

The financing was led by Flagship Ventures, Polaris Partners, and Third Rock Ventures. Partners Innovation Fund also participated.

Editas plans to use its genome editing technology to develop new therapeutics “that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.